

Cell-Replacement Therapy with Stem Cells in Neurodegenerative Diseases

Vincenzo Silani* and Massimo Corbo

Department of Neurology and Laboratory of Neuroscience – “Dino Ferrari” Center, University of Milan Medical School – IRCCS Istituto Auxologico Italiano, Milano, Italy

Abstract: In the past few years, research on stem cells has expanded greatly as a tool to develop potential therapies to treat incurable neurodegenerative diseases. Stem cell transplantation has been effective in several animal models, but the underlying restorative mechanisms are still unknown. Several mechanisms such as cell fusion, neurotrophic factor release, endogenous stem cell proliferation, and transdifferentiation may explain positive therapeutic results, in addition to replacement of lost cells. The biological issue needs to be clarified in order to maximize the potential for effective therapies. The absence of any effective pharmacological treatment and preliminary data both in experimental and clinical settings has recently identified Amyotrophic Lateral Sclerosis (ALS) as an ideal candidate disease for the development of stem cell therapy in humans. Preliminary stem transplantation trials have already been performed in patients. The review discusses relevant topics regarding the application of stem cell research to ALS but in general to other neurodegenerative diseases debating in particular the issue of transdifferentiation, endogenous neural stem cell, and factors influencing the stem cell fate.

Key Words: Amyotrophic lateral sclerosis, Neurodegenerative disease, Stem cell, Transplantation.

INTRODUCTION

Amyotrophic Lateral Sclerosis (ALS), after Charchot's first definition and in relation to Lou Gehrig's centennial birthday in 2003, still remains a lethal disease. Due to the absence of any effective remedy and supporting preliminary data, both in experimental and clinical settings for treating ALS, the possibility of developing stem cell therapy in humans using ALS as a candidate disease has been recognized recently by the scientific community. Over the past two decades, extensive experiments, beginning with fetal neuron transplantation in Parkinson's disease (PD) animal models, have provided the basic proof of principle for cell replacement (Brundin and Hagell, 2001). The observed positive results have spearheaded the development of this therapeutic approach even in humans. Patients affected by PD, Huntington's (HD) and, more recently, ALS have been approached. Despite these promising results, significant constraints still hamper the use of embryonic cells for neurotransplantation (Bjorklund and Lindvall, 2000). Besides, the ethical concerns related to the use of material, the viability, purity, and phenotype final destiny of the fetal cells have not been completely defined. The recent breakthroughs in SC research have opened up new possibilities for cell-replacement therapy since these cells can be indefinitely expanded in number and cryopreserved even for long periods without losing their potentiality. The use of SCs overcomes

the need of synchronization between donation and transplant, the problem of limited donor cell number and, at the same time, it discloses the novel possibility of employing autologous sources.

ALS AS A CANDIDATE DISEASE FOR CELL-REPLACEMENT THERAPY

ALS is a lethal disease characterized by the degeneration and death of both upper and lower motor neurons. The course of the disease is relentless and progresses without remissions, relapses, or even stable plateaus. Its pathogenesis is probably multifactorial and includes the interaction of several susceptibility genes, undetermined environmental factors, and the physiological cellular aging (Rowland and Scheider, 2001).

In the last few years, several drug therapies based on known or suspected etiopathogenetic mechanisms have been translated into clinical trials. However, they failed to arrest degeneration and restore motor function. Therefore, an alternative strategy has been sought for effective treatment. Neural transplantation in the past and SC therapy now seem to be two of the most promising answers to this problem (Silani *et al.*, 2002).

The large majority of ALS patients are sporadic cases (SALS) and only 5-10% of patients show familial inherited forms (FALS) associated to mutations in the Cu/Zn superoxide dismutase-1 (SOD1) gene in a small proportion (15-20%) (Gaudette *et al.*, 2000). This gene encodes the copper- and zinc-dependent SOD1 with a possible cytotoxic activity in the mutant form due to an abnormal protein folding. Mutant SOD1-G93A mice exhibit progressive degeneration of lower motor neurons, decreased stride, and muscle strength with death occurring at 4-5 months of age.

*Address correspondence to this author at the Department of Neurology and Laboratory of Neuroscience, “Dino Ferrari” Center – University of Milan Medical School, IRCCS Istituto Auxologico Italiano, Via Spagnoletto 3, 20149 Milano, Italy; Tel: ++39 02 61911 2982; Fax: ++39 02 61911 2937; E-mail: vincenzo@silani.com

Received: February 4, 2004; Revised: March 5, 2004; Accepted: March 11, 2004

Thus, this FALS model became a convenient tool not only for understanding the pathogenesis, but also for developing new therapeutic strategies (Wong *et al.*, 2002). Positive effects on the onset of motor dysfunction and on the average lifespan were observed after human NT neurons transplantation into the ventral horn spinal cord of SOD1G93A mice (Garbuzova-Davis *et al.*, 2002). Also human umbilical cord blood mononuclear and bone marrow SC infusions were reported to substantially increase mice lifespan with a dose dependent effect, although no human DNA was detected in the host tissues (Chen and Ende, 2000; Ende *et al.*, 2000). Similar results were obtained by Garbuzova-Davis *et al.* (Garbuzova-Davis *et al.*, 2003) where human umbilical cord blood cells, administrated intravenously to presymptomatic SOD1G93A mice, were shown to migrate preferentially towards degenerated sites, but also to peripheral organs. In addition, expression of neural markers by few human transplanted cells was demonstrated and an overall neuroprotection effect was suggested to be the main cause of the observed benefits.

Recently, two preliminary papers reported a limited series of ALS cases grafted with blood SCs. Janson *et al.* (Janson *et al.*, 2001) intrathecally injected peripheral blood SCs in three ALS patients. FACS purified CD34⁺ cells were administrated and after 6-12 months none of the patients reported side effects; but no significant clinical efficacy was reported during following evaluations. More recently, Mazzini *et al.* (Mazzini *et al.*, 2003) injected autologous bone marrow derived cells after expansion *in vitro* in 7 patients affected by ALS. The transplantation procedure was performed after resuspension of the cells in the autologous cerebrospinal fluid and direct injection into the surgically exposed spinal cord at T7-T9 levels. According to the authors, none of the patients manifested severe side-effects; only minor adverse effects were reported, such as reversible intercostal pain and reversible leg sensory dysesthesia. Neuroradiological examinations were normal and no significant psychological status or quality of life modifications were reported. However, the clinical efficacy of the transplant is still under evaluation. The authors concluded that these procedures were "safe and well tolerated by ALS patients" (Mazzini *et al.*, 2003).

Even if additional data related to clinical efficacy are not available, cell transplantation into the human cord seems to be feasible and other grafting programs in ALS have just been started (Vastag, 2001). Nevertheless, while patients are desperately trying to enroll in SC clinical trials, caution and careful evaluation of the preliminary results, especially considering the issues of transdifferentiation and transplantation, are necessary before widely applying such a pioneer technique (Silani and Leigh, 2003). More recently, two papers demonstrated, in two different animal models of motor neuron disease, the efficacy of human pluripotent cells to restore functions in paralyzed rats (Kerr *et al.*, 2003) and the influence of adjacent cells in the long-term survival of SOD1G93A motor neurons (Clement *et al.*, 2003). In particular, this last evidence provides the strongest support to the stem cell implementation therapy, sustaining the possibility of inducing clinical recovery by increasing the number of unaffected non-neuronal (astroglial) cells.

STEM CELL POTENTIALS

SCs are undifferentiated multipotent cells capable of both self-renewal and generation of several differentiated cell types (Potten and Loeffler, 1990; Morrison *et al.*, 1997; Labat, 2001). It is proved that they are present until adulthood in almost all tissues and organs (i.e. hematopoietic, neural, muscle, intestinal crypt, and skin SCs) where they preserve homeostasis of cell number (Weissman *et al.*, 2001; Verfaillie *et al.*, 2002). SCs are also characterized by extensive plasticity, (a feature reported repeatedly in recent pieces of literature), by which a tissue-specific cell can either dedifferentiate or transdifferentiate into a novel unrelated phenotype. These two processes are thought to occur mainly through DNA transcriptional activation and through repression due to chromatin structure modifications (i.e. histone methylation and acetylation) determined by intrinsic and extrinsic growth factors (Tada and Tada, 2001). SC proliferation kinetic is tissue-specific and it is influenced by genetic and environmental clues, such as developmental stage and mitogen supply (Monna *et al.*, 2000; van Heyningen *et al.*, 2001; Peterson, 2002). As a matter of fact, during embryogenesis, SCs contribute at first to organ formation through a massive symmetric cell division mode aimed at increasing the cell number. Later, there is a switch towards a preferential asymmetric division in order to give rise to slightly differentiated cells or "progenitors", which in turn, can originate fully differentiated progeny (Temple, 2001). Progenitors, in opposition to SCs, show a limited self-renewal capacity and are often unipotent (Seaberg and van der Kooy, 2003). SC number decreases in favor of progenitors and functional, fully differentiated cells, during an organism's lifespan, since at least in animals, stem cell proliferation reduces with age (Fallon *et al.*, 2000). In the long term, this process diminishes the rate of neurogenesis, and seems to be strictly related to telomere shortening and stem cell cycle extension (Taupin and Gage, 2002). In the adult, the SC compartment may be present in a relatively quiescent state in relation to the tissue, specifically, in a finely tuned and dynamic balance between the proliferative and the resting conditions. Perturbation of this equilibrium by environmental factors, such as severe lesions or injuries, may induce the exit of SCs from the quiescent state and their proliferation in order to restore the lost/damaged cell population(s). SC flexible sensitivity to the surroundings is maintained in culture and, for example, can be used to generate nearly pure neuronal populations from human fetal neural SCs for transplantation into adult rat central nervous system (CNS) (Wu *et al.*, 2002).

Several kinds of SCs were shown to integrate into the blastocyst and give rise to almost all differentiated tissues (Geiger *et al.*, 1998; Clarke *et al.*, 2000; Jiang *et al.*, 2002). Therefore, SC seems to be a complex biological entity in continuous evolution in relation to its genetic program and the surrounding microenvironment rather than a discrete, independently existing cellular type (Leminska, 2002; Vernig and Brustle, 2002).

Dedifferentiation occurs when a cell reverts to an earlier and more immature state with the expression of primitive markers, usually detected during the differentiation pathway. This dedifferentiative capacity is normally absent in mam-

malian cells, but it has been proved that at least myotubes possess this property in a permissive environment (Odelberg *et al.*, 2001). When the cell fate change is rapid and doesn't involve a passage back to early progenitor cells, the process is referred to as transdifferentiation. This may occur both within the same tissue (i.e. a glial cell reverts to a neuron) and in different tissue derivatives (i.e. a hematopoietic cell acquires a neural phenotype). It has been shown that hematopoietic SCs are able to transdifferentiate into neural cells (Brazelton *et al.*, 2000; Mezey *et al.*, 2000) and vice versa (Bjorson *et al.*, 1999). Moreover mesenchymal and skin SCs may convert to a neural phenotype (Eglitis and Mezey, 1997; Toma *et al.*, 2001). Such transdifferentiation event seems to be restricted not only to SCs, but has also been observed in progenitors and differentiated cells (Kondo and Raff, 2000; Malatesta *et al.*, 2000).

All these recent reports have created much excitement in scientific community due to the possibility of exploiting the transdifferentiation mechanism combined with SC properties (capacity of unlimited self-renewal plus potential to exponentially generate several types of differentiated progeny) for cell replacement therapy. As a matter of fact, easily accessible autologous SCs could then represent a source for therapeutical transplantation when a specific cell population is lost or damaged. Therefore, investigation on this topic has been boosted in the last few years but, as we will discuss in the following paragraphs, the results are still controversial.

STEM CELLS AND NEURODEGENERATIVE DISEASES

In neurodegenerative diseases, drugs can alleviate symptoms and relieve pain, but up to now they have not been able to permanently repair damaged tissues. It has been proposed that SC persistence in adult organs could be a compensatory mechanism which contributes to self-repair under normal conditions, but fails in particular circumstances or tissues, such as in the case of a wide neurodegeneration (Armstrong and Barker, 2001; Kuhn *et al.*, 2001). Even though plastic adult neurogenesis has been demonstrated in specific brain regions (i.e. subventricular zone and hippocampal dentate gyrus) even in humans, the CNS demonstrates a remarkably limited capacity for self-repair. This phenomenon is probably due to the lack of suitable signals able to activate a sufficient number of endogenous neural stem cells and then to instruct appropriate cell differentiation (Peterson, 2002). Focalized extensive neuronal cell death caused by stroke in adult brains triggers proliferation/recruitment of neuroblasts, and newly generated neurons are reported to migrate from subventricular zone to damaged area (Arvidsson *et al.*, 2002). Additional papers demonstrate proliferation/differentiation of endogenous neural SCs (Fallon *et al.*, 2000; Peterson, 2002; Nakatomi *et al.*, 2002; Schmidt and Reymann, 2002), even in normally non-neurogenic regions (Johansson *et al.*, 1999). Unfortunately, the physiological action of the newly generated neurons has not been completely proved and, just the same, it is not sufficient to produce a functional recovery (Yamamoto *et al.*, 2001; Magavi and Macklis, 2002).

Adult neurogenesis can be stimulated «*in situ*» by intraventricular infusions of basic Fibroblast Growth Factor (bFGF) and Epidermal Growth Factor (EGF) following

global ischemia (Nakatomi *et al.*, 2002) and in intact brain (Palmer *et al.*, 1999; Gould *et al.*, 1999). Similarly, the expansion of brain neuroprecursor cells can be enhanced by Brain Derived Nerve Growth Factor (BDNF); (Benraiss *et al.*, 2001), Ciliary Neurotrophic Factor (CNTF); (Shimazaki *et al.*, 2001) and Noggin gene activation (Lim *et al.*, 2000). These observations suggest that a limited availability of appropriate growth factors combined with the presence of repressive signals practically restricts the brain regeneration potential.

Since reduced neurotrophic support is likely to be correlated to the pathogenesis of neurodegenerative disorders such as Alzheimer disease (AD), PD, HD, and ALS, neurotrophin administration in clinical trials is actually under study, but with no apparent success so far (Zuccato *et al.*, 2001; Dawbarn and Allen, 2003). The only exception is the insulin growth factor 1 (IGF-1) adenovirus associated delivery in an ALS animal model, which was reported to prolong survival (Kaspar *et al.*, 2003). On the other hand, riluzole (2-amino-6-trifluoromethoxy-benzothiazole), an antiexcitotoxic agent partially effective in the treatment of ALS patients, was also shown to induce neurotrophic effects in animal models of PD, HD and brain ischemia (Doble, 1996; Palfi *et al.*, 1996; Guyot *et al.*, 1997). It has been proved that it stimulates Nerve Growth Factor (NGF), BDNF, and Glial Cell Line-Derived Neurotrophic Factor (GDNF) release in cultured mouse astrocytes and *in vivo* in the rat hippocampus (Mizuta *et al.*, 2001; Katoh-Semba *et al.*, 2002).

A hypothetical scenario for adult human brain cell repair would therefore combine transplantation of donor stem/progenitor cells, purposely purified and committed towards the differentiated requested phenotype, with growth factors/drugs administration and eventually biomatrices in order to stimulate axon development and synaptogenesis (Steindler and Pincus, 2002).

MECHANISMS OF ACTION AND TROUBLES IN TRANSPLANTATION/ TRANSDIFFERENTIATION

Experience with human fetal cell transplantation, especially in PD, has demonstrated that results of clinical trials are quite variable among groups of patients receiving the same cell preparation. Several different parameters (such as patient conditions, graft location, type of transplanted tissue/cells, etc.) seem to affect the positive integration and survival of dopaminergic neurons in the host brain (Dunnet *et al.*, 2001). For example, cell suspension was demonstrated to be more effective for reconstitution of lost connection and recovery in comparison to small tissue pieces in the case of fetal grafts (Isacson *et al.*, 2003).

Identification and isolation of pure SCs is hard to achieve because of the absence of specific antigens. Although some markers have been identified so far, they cannot be used to univocally separate stem population from progenitors, which possess a limited proliferative self-renewing capacity and are often even unipotent (Seaberg and van der Kooy, 2003). This practical problem has to be carefully considered if SCs are to be used for transplantation purposes and clinical applications. The optimal cell therapy should exploit a pure and well-characterized population in order to achieve the best results (Rossi and Cattaneo, 2002), since both experimental

and clinical trials are actually limited by mixed cellular composition and low neuronal yield, i.e. dopaminergic neurons (Isacson *et al.*, 2003).

Nevertheless, some antigens allow for discriminating among tissue-specific stem populations (i.e. cell surface markers CD133 and CD34 are mainly used for hematopoietic SCs) (Weissman *et al.*, 2001; Verfaillie *et al.*, 2002), but in several cases we are still far from a clear identification and tracking of SCs, and this issue is particularly relevant for neural stem cells. As a matter of fact, antigens such as musashi1, nestin, Sox1, Sox2, SSEA-1/LeX have been proposed as possible markers for neural SC selection, but they only enrich stem ratio instead of providing a pure stem population (Sakakibara and Okano, 1997; Cai *et al.*, 2003). Nestin, an intermediate filament protein, is also expressed in myoblasts and endothelial cells (Wroblewski, 1997; Johansson *et al.*, 1999) and therefore may not be considered a reliable marker for NSC selection. Fine separation techniques based on negative fluorescence-activated cell sorting (FACS) (in order to exclude lineage-restricted cells) and immunomagnetic beads have also been recently developed in order to obtain purified and homogeneous stem populations (Cai *et al.*, 2003).

Recent gene expression profile studies show that SCs of different origins (ES, hematopoietic, neural stem cells) share a common genetic program together with a tissue-specific gene expression (Ivanova *et al.*, 2002; Ramalho-Santos *et al.*, 2002). These oligonucleotide microarray data may help elucidate the key genes or regulatory pathways that may be necessary to maintain the stem condition and, at the same time, to obtain a switch in SC fate for clinical applications. Experimental data reveal that both adult mouse bone marrow and neurally derived SCs injected into blastocyst can generate chimeric mice (Geiger *et al.*, 1998; Clarke *et al.*, 2000), thus demonstrating a complete nuclear reset. On the other hand, a precise sequence of epigenetic signals can modulate gene expression and is required for both tissue specification during normal embryogenesis and acquisition of a novel cell fate, as has been reported for hematopoietic lineage development induced from human muscle and neural tissue (Jay *et al.*, 2002). Similar regulatory mechanisms are known to be active also *in vitro*: the use of Leukemia Inhibitory Factor (LIF) cytokine, in fact, is reported to exert a positive effect on neural SC cultures increasing their growth rates and prolonging their self-renewal capacity (Wring *et al.*, 2003). The molecular data collected from microarray studies on LIF-treated NSC may be useful to discriminate genes/pathways that are important for maintaining long-term NSC cultures.

Presently, the transdifferentiation event is viewed with criticism: reports are continuously published in favor or against the future clinical exploitation of this possibility. Recently, for example, it has been published that marrow stromatal cells can generate neurons *in vitro* (Munoz-Elias *et al.*, 2003), that umbilical cord blood SC infusion ameliorates functional defects in spinal cord injury (Saporta *et al.*, 2003) and that fetal hematopoietic SCs can give rise, sequentially, to neurons and then astrocytes in culture (Hao *et al.*, 2003). Transdifferentiation process requires activation of specific genes as was demonstrated for myelin genes in transfor-

mation of murine melanoma into glial cells (Slutsky *et al.*, 2003). These observations coincide with the findings of bone marrow-generated neurons after transplantation into human leukemic patients (Mezey *et al.*, 2003) and of improvements of neurological defects by bone marrow grafts after ischemia (Zhao *et al.*, 2002). A novel functionality has also been found to be acquired after transdifferentiation of endothelial progenitor cells into active cardiomyocytes (Badoff *et al.*, 2003).

On the other hand, several cases and reports against the natural occurrence of cellular change of fate are continuously published. After many contradictory reports, Jlang and colleagues (2002) described the existence of a rodent and human bone marrow sub-population, co-purifying with mesenchymal stem cells, termed multipotent adult progenitor cells or MAPCs. These cells were able to differentiate, at the single cell level, in cells with mesoderm, endoderm, and neuroectoderm characteristics *in vitro* and *in vivo* after transplantation, showing extensive proliferation without loss of differentiation potential, similarly to embryonic SC (ES). Even better results have been achieved *in vitro* with human hematopoietic SCs obtained from the umbilical cord, demonstrated to differentiate sequentially into neuronal SCs and then astrocytes after exposure to suitable microenvironment (Hao *et al.* 2003).

Recently, however, transdifferentiation has been debated and a number of other biological explanations have been put forward. Cell fusion, specifically, has been heavily advocated as an alternative to transdifferentiation (Terada *et al.* 2002). Perhaps, the most knowledgeable conclusion to draw is that transdifferentiation is an uncommon phenomenon that takes place only under very peculiar circumstances. In fact, adult hematopoietic SCs are reported to reconstitute a lost leukocyte population, but they are not appreciably integrated into other tissues such as muscle, brain, gut, liver and kidney (Wagers *et al.*, 2002). In one recent report, hematopoietic potential of muscle SCs was due to contamination of the donor cells instead of real transdifferentiation (McKinney-Freeman *et al.*, 2002). Conversely, no apparent neuronal differentiation was found in a significant number of animals, either lethally irradiated or presenting neuronal injury, after whole bone marrow cell transplantation (Castro *et al.*, 2002). Finally, bone marrow cells, migrating in the adult brain 4-18 weeks after transplantation, fail to transform into neural cells and preserve their hematopoietic properties (Ono *et al.*, 2003) and transdifferentiation of freshly dissociated brain cells into blood was not proven (Magrassi *et al.*, 2003). Cell fusion was also considered the main source of bone marrow-derived hepatocytes (Wang *et al.*, 2003; Vassipoulos *et al.*, 2003).

All this data suggests that plasticity is rare and needs an important cellular deficit and/or niche pushing for proliferation and localized accumulation of donor cells in the lesioned site (Wagers *et al.*, 2002). An «ideal» condition combines the generation of appropriate chemokine signals, specific adhesion proteins, and the depletion of endogenous SC population in order to maximize the transplanted cell contribution. These conditions are usually achieved in experiments with host irradiation; but this procedure induces endogenous neural progenitor dysfunction due to a mutated

microenvironment with an increase in glial cell number at the expense of new neurons, as has been recently demonstrated (Monje *et al.*, 2002) and therefore, may have limited applications in patients.

How is it possible to conciliate these apparently opposing data on transdifferentiation? First we have to keep in mind that the experimental conditions vary a lot among different laboratories and that even a sorted purified SC population is heterogeneous «*per se*». For example, Ianus *et al* (Ianus *et al.*, 2003) have recently demonstrated the existence of a candidate pancreatic progenitor in bone marrow, which can be activated and made to proliferate in response to circulating signals, giving rise to functional active pancreatic β cells. Therefore, in the absence of specific selective markers, the purification of a SC population is impossible to achieve and contamination by different tissue stem/progenitors cannot be excluded. Probably the transdifferentiation process and/or the clinical improvements derive even from interactions of different cellular subsets, reciprocally providing cytokines, growth factors, and intercellular signals. The neural SC transplantation in an animal model of multiple sclerosis determines a clinical improvement that is accompanied by remyelination. This remyelination is directed by transplanted precursors and probably by a reduced reactive astrogliosis – a negative regulator of endogenous oligodendrocyte proliferation (Pluchino *et al.*, 2003). Cooperation and/or synergistic action between endogenous stem and transplanted cells could therefore be indispensable for a functional recovery. Dissection of such complex interacting mechanisms could be very difficult to gain.

Cell fusion has been advocated and even demonstrated in several reports in order to explain an apparent transdifferentiation event (Terada *et al.*, 2002; Wurmser and Gage, 2002; Ying *et al.*, 2002), but it has been recently proposed that this mechanism could represent a normal pathway towards differentiation and repair in damaged tissues (Blau, 2002).

Several recent reviews have tried, with limited success so far, to clarify and set the precise requirements, such as functional integration and specific antigen acquisition, necessary for a transplanted SC to be considered differentiated and/or transdifferentiated (Joshi and Enver, 2002; Alison *et al.*, 2003; Collas and Hakelien, 2003; Greco and Recht, 2003; Liu and Rao, 2003; Moore and Quesenberry, 2003).

Finally, since so many mechanisms and pathways could be involved during and after transdifferentiation/clinical transplantation, it's not too surprising that a complex mass of opposite results derives from different experiments and that therefore a clear scenario on these processes is still far from being achieved.

CONCLUSIONS

Only after SC differentiation mechanisms are fully understood, promising treatment strategies can be designed to redirect adult SCs to regenerate motor neurons in a clinically relevant manner in ALS patients. Furthermore, ALS requires, for the regeneration of the lower and upper motor neurons, a specific strategy for the cell replacement approach. In fact, the functional integration in the neuronal circuitry must be obtained after having restabilized the

complex and precise connectivity of the implanted cells. In light of the above considerations, even if ALS is a desperate disease that, more than others, is able to induce the patient to seek innovative therapeutical strategies, at the same time it also provides a real challenge to the clinician and the neurobiologist who need to define a new approach to simultaneously restore the degenerating cortico-spinal tract and the lower motor neurons. Finally, it is crucial that the medical-scientific and the medical-media communities work together to keep the general public well informed, but also realistically appraised as to the significance of scientific breakthroughs in the development of new treatments related to ALS (Silani and Leigh, 2003).

ACKNOWLEDGEMENTS

The authors would like to thank John P. Hemingway for critically reading the manuscript. Supported in part by a grant from IRCCS Istituto Auxologico Italiano, Dr. Angelo Mauri's donation, and Fondazione Italo Monzino.

REFERENCES

- Alison, MR, Poulosom, R, Otto, WR, Vig, P, Brittam, M, Direkze, NC, Preston, L, Wright, NA. (2003) Plastic adult stem cells: will they graduate from the school of hard Knocks? *J Cell Science* **116**: 599-603.
- Armstrong, RJE, Barker, RA. (2001) Neurodegeneration: a failure of neuroregeneration? *Lancet* **358**: 1174-1176.
- Arvidsson, A, Collin, T, Kirik, D, Kokaia, Z, Lindvall, O. (2002) Neuronal replacement from endogenous precursors in the adult brain after stroke. *Nat Med* **8**: 963-970.
- Badoff, C, Braudes, RP, Popp, R, Rupp, S, Urbich, C, Aicher, A, Fleming, I, Busse, R, Zeiher, AM, Dimmeler, S. (2003) Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes. *Circulation* **107**: 1024-1032.
- Benraiss, A, Lerner, K, Chmielnicki, E, Roth, D, Goldmann, SA. (2001) Adenoviral brain-derived neurotrophic factor induces both neurostriatal and olfactory neuronal recruitment from endogenous progenitor cells in the adult forebrain. *J Neurosci* **21**: 6718-6731.
- Bjorklund A and Lindvall O. Cell replacement therapies for central nervous system disorders (2000) *Nature Neurosci* **3**, 537-544.
- Bjorson, CRR, Rietze, RL, Reynolds, BA, Magli, MC, Vescovi, AL. (1999) Turning brain into blood: a hematopoietic fate adopted by adult neural stem cell *in vivo*. *Science* **283**: 534-537.
- Blau, HM. (2002) A twist of fate. *Nature* **419**: 437.
- Brazelton, TR, Rossi, FM, Keshet, GI, Blau, HM. (2000) From marrow to brain: expression of neuronal phenotypes in adult mice. *Science* **290**: 1775-1779.
- Brundin P and Hagell P (2001) The neurobiology of cell transplantation in Parkinson's disease. *Clin Neurosci Res* **1**, 507-520.
- Cai, J, Limke, TL, Ginis, I, Rao, S. (2003) Identifying and tracking neural stem cells. *Blood Cells Mol Dis* **31**: 18-27.
- Castro, RF, Jackson, K, Goodell, MA, Robertson, CS, Liu, H, Shine, HD. (2002) Failure of bone marrow cells to transdifferentiate into neural cells *in vivo*. *Science* **297**: 1299.
- Chen, R, Ende, N. (2000) The potential for the use of mononuclear cells from human umbilical cord blood in the treatment of amyotrophic lateral sclerosis in SOD1 mice. *J Med* **31**: 21-30.
- Clarke, DL, Johansson, CB, Wilberts, J, Veress, B, Nilson, E, Karlstrom, H, Lendahl, U, Frisén, J. (2000) Generalized potential of adult neural stem cells. *Science* **288**: 1660-1663.
- Clement, AM, Nguyen, MD, Roberts, EA, Garcia, ML, Boillée, S, Rule, M, McMahon, AP, Doucette, W, Slwek, D, Ferrante, RJ, Brown Jr, RH, Julien, JP, Goldstein, LSB, Cleveland, DW. (2003). Wild-Type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. *Science* **203**: 113-117.
- Collas, P, Hakelien, AM. (2003) Teaching cells new tricks. *Trends Biotech* **21**: 354-361.
- Dawbarn, D, Allen, SJ. (2003) Neurotrophins and neurodegeneration. *Neuropathol Appl Neurobiol* **29**: 211-230.
- Doble, A. (1996) The pharmacology and mechanism of action of riluzole. *Neurology* **47**: S233-241.

- Dunnet, SB, Bjorklund, A, Lindvall, O. (2001) Cell therapy in Parkinson's disease: stop or go? *Nat Rev Neurosci* **2**: 365-369.
- Eglitis, MA, Mezey, E. (1997) Hematopoietic cells differentiate into both microglia and macroglia in the brain of adult mice. *Proc Natl Acad Sci USA* **8**: 4080-4085.
- Ende, N, Weistein, F, Chen, R, Ende, M. (2000) Human umbilical cord blood effect on sod mice (amyotrophic lateral sclerosis). *Life Sci* **67**: 53-59.
- Fallon, J, Reid, S, Kinyamu, R, Opole, I, Opole, R, Baratta, J, Korc, M, Endo, TL, Duong, A, Nguyen, G, Karkehabadhi, M, Twardzik, D, Patel, S, Loughlin, S. (2000) *In vivo* induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain. *Proc Natl Acad Sci* **97**: 14686-14691.
- Garbuzova-Davis, S, Willing, AE, Millken, M, Saporta, S, Zigova, T, Cahill, DW, Sanberg, PR. (2002) Positive effect of transplantation of hNT neurons (NTERA 2/dl cell-line) in a model of familial amyotrophic lateral sclerosis. *Exp Neurol* **174**: 169-180.
- Garbuzova-Davis, S, Willing, AE, Zigova, T, Saporta, S, Justen, EB, Lane, JC, Hudson, JE, Chen, N, Davis, CD, Sanberg, PR. (2003) Intravenous administration of human umbilical cord blood cells in mouse model of amyotrophic lateral sclerosis: distribution, migration, and differentiation. *J Hematother Stem Cell Res* **12**: 255-270.
- Gaudette, M, Hirano, M, Siddique, T. (2000) Current status of SOD1 mutations in familial amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor Neuron Disord* **1**: 83-89.
- Geiger, H, Sick, S, Bonifer, C, Muller, AM. (1998) Globin gene expression is reprogrammed in chimeras generated by injecting adult hematopoietic stem cells into mouse blastocysts. *Cell* **93**: 1055-1065.
- Gould, E, Reeves, AJ, Graziano, MS, Gross, CG. (1999) Neurogenesis in the neocortex of adult primates. *Science* **286**: 548-552.
- Greco, B, Recht, L. (2003) Somatic plasticity of neural stem cells: fact or fancy?. *J Cell Biochem* **88**: 51-56.
- Guyot, MC, Palfi, S, Stutzmann, JM, Maziere, M, Hantraye, P, Brouillet, E. (1997) Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats. *Neuroscience* **81**: 141-149.
- Hao, HN, Zhao, J, Thomas, RL, Parker, GC, Lyman, WD. (2003) Fetal human hematopoietic stem cells can differentiate sequentially into neural stem cells and then astrocytes *in vitro*. *J Hematother Stem Cell Res* **12**: 23-32.
- Ianus, A, Holz, GG, Theise, ND, Hussain, MA. (2003) *In vivo* derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. *J Clinical Invest* **111**: 843-850.
- Isacson, O, Bjorklund, LM, Shumacher, JM. (2003) Toward a full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells. *Ann Neurol* **53** (Suppl 3): III/135-148.
- Ivanova, NB, Dimos, JT, Schaniel, C, Hackney, JA, Moore, KA, Lemichka, IR. (2002) A stem cell molecular signature. *Science* **298**: 601-604.
- Janson, CG, Rameh, TM, During, MJ, Leone, P, Heywood, J. (2001) Human intrathecal transplantation of peripheral blood stem cells in amyotrophic lateral sclerosis. *J Hematother Stem Cell Res* **10**: 913-915.
- Jay, KE, Gallacher, L, Bhatia, M. (2002) Emergence of muscle and neural hematopoiesis in humans. *Blood* **100**: 3193-3202.
- Jiang, Y, Jahagirdar, BN, Reinhardt, RL, Schwartz, RE, Keene, CD, Ortiz-Gonzalez, XR, Reyes, M, Lenvik, T, Lund, T, Blackstad, M, Du, J, Aldrich, S, Lisberg, A, Low, WC, Largaespada, DA, Verfaillie CM. (2002) Pluripotency of mesenchymal stem cells derived from adult marrow. *Nature* **418**: 41-49.
- Jiang, Y, Vassen, B, Lenvik, T, Blackstad, M, Reyes, M, Verfaillie, CM. (2002) Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle and brain. *Exp Hematol* **30**: 896-904.
- Johansson, CB, Momma, S, Clarke, DL, Risling, M, Lendhal, U, Frisen, J. (1999) Identification of a neural stem cell in the adult mammalian central nervous system. *Cell* **96**: 25-34.
- Johansson, CB, Svensson, M, Wallsted, L, Janson, AM, Frisen, J. (1999) Neural stem cells in the adult human brain. *Exp Cell Res* **253**: 733-736.
- Joshi, CV, Enver, T. (2002) Plasticity revisited. *Curr Opin Cell Biol* **14**: 749-755.
- Kaspar, BK, Liadó, J, Sherkat, N, Rpthtein, JD, Gage, FH. (2003) Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. *Science* **301**: 839-842.
- Katoh-Semba, R, Asano, T, Ueda, H, Morihita, R, Takeuchi, IK, Inaguma, Y, Kato, K. (2002) Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. *FASEB J* **16**: 1328-1330.
- Kerr, DA, Llado, J, Shablott, MJ, Maragakis, NJ, Irani, DN, Crawford, TO, Krishnan, C, Dike, S, Gearhart, JD, Rothstein, JD. (2003) Human embryonic germ cell derivatives facilitate motor recovery of rats with diffuse motor neuron injury. *J Neurosci* **23**: 5131-5140.
- Kondo, T, Raff, M. (2000) Oligodendrocyte precursor cells reprogrammed to become multipotential CNS stem cells. *Science* **289**: 1754-1757.
- Kuhn, HG, Palmer, TD, Fuchs, E. (2001) Adult neurogenesis: a compensatory mechanism for neural damage. *Eur Arch Psychiatric Clin Neurosci* **251**: 152-158.
- Labat, ML. (2001) Stem cells and the promise of eternal youth: embryonic versus adult stem cells. *Biomed Pharmacother* **55**: 179-185.
- Leminska, I. (2002) A few thoughts about plasticity of stem cells. *Exp Hematol* **30**: 848-852.
- Lim, DA, Tramontin, AD, Trevejo, JM, Herrera, DG, Garcia-Verdugo, JM, Alvarez-Buylla, A. (2000) Noggin antagonizes BMP signaling to create a niche for adult neurogenesis. *Neuron* **28**: 713-726.
- Liu, Y, Rao, MS. (2003) Transdifferentiation: fact or artifact. *J Cell Biochem* **88**: 29-40.
- Magavi, SS, Macklis, JD. (2002) Immunocytochemical analysis of neuronal differentiation. *Meth Mol Biol* **198**: 291-297.
- Magrassi, L, Castello, S, Ciardelli, L, Podesta, M, Gasparoni, A, Conti, L, Pezzotta, M, Frassoni, F, Cattaneo, E. (2003) Freshly dissociated fetal neural stem/progenitor cells do not turn into blood. *Mol Cell Neurosci* **22**: 179-187.
- Malatesta, P, Hartfuss, E, Gotz, M. (2000) Isolation of radial glial cells by fluorescent-activated cell sorting reveals a neuronal lineage. *Development* **127**: 5253-5263.
- Mazzini, L, Fagioli, F, Boccaletti, R, Mareschi, K, Oliveri, G, Oliveri, C, Pastore, I, Marasso, R, Madon, E. (2003) Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. *Amyotroph Lateral Scler Other Motor Neuron Disord* **4**: 158-161.
- McKinney-Freeman, SL, Jackson, KA, Camargo, FD, Ferrari, G, Mavilio, F, Goodell, MA. (2002) Muscle-derived hematopoietic stem cells are hematopoietic in origin. *Proc Natl Acad Sci USA* **99**: 1341-1346.
- Mezey, E, Chandross, KJ, Harta, G, Maki, RA, McKercher, SR. (2000) Turning blood into brain: cell bearing neuronal antigens generated *in vivo* from bone marrow. *Science* **290**: 1779-1782.
- Mezey, E, Key, S, Vogelsang, G, Szalayova, I, Lange, GD, Crain, B. (2003) Transplanted bone marrow generates new neurons in human brains. *Proc Natl Acad Sci USA* **100**: 1364-1369.
- Mizuta, I, Ohta, M, Ohta, K, Nishimura, M, Mizuta, E, Kuno, S. (2001) Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor and synthesis in cultured mouse astrocytes. *Neurosci Lett* **310**: 117-120.
- Momma, S, Johansson, CB, Frisen, J. (2000) Get to know your stem cells. *Curr Opin Neurobiol* **10**: 45-49.
- Monje, ML, Mizumatsu, S, Fike, JR, Palmer, TD. (2002) Irradiation induces neural stem cell dysfunction. *Nat Med* **8**: 955-962.
- Moore, BE, Quesenberry, PJ. (2003) The adult hemopoietic stem cell plasticity debate: idols vs new paradigms. *Leukemia* **17**: 1205-1210.
- Morrison, SJ, Shah, NM, Anderson, D. (1997) Regulatory mechanisms in stem cell biology. *Cell* **88**: 287-298.
- Munoz-Elias, G, Woodbury, D, Black, IB. (2003) Marrow stromal cells, mitosis, and neuronal differentiation: stem cell and precursor functions. *Stem Cells* **21**: 437-448.
- Nakatomi, H, Kuriu, T, Okabe, S, Yamamoto, S, Hatano, O, Kawahara, N, Tamura, A, Kirino, T, Nakafuku, M. (2002) Regeneration of hippocampal pyramidal neurons after ischemic brain injury by recruitment of endogenous neural progenitors. *Cell* **110**: 429-441.
- Odelberg, SJ, Kollhoff, A, Keating, MT. (2001) Dedifferentiation of mammalian myotubes induced by *msx1*. *Cell* **103**: 1099-1099.
- Ono, K, Yoshihara, K, Suzuki, H, Tanaka, KF, Takii, T, Onozaki, K, Sawada, M. (2003) Preservation of hematopoietic properties in transplanted bone marrow cells in the brain. *J Neurosci Res* **72**: 503-507.
- Palfi, S, Ferrante, RJ, Brouillet, E, Beal, MF, Dolan, R, Guyot, MC, Paschanski, M, Hantraye, P. (1996) Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of HD disease. *J Neurosci* **16**: 3019-3025.
- Palmer, TD, Markakis, EA, Willhoite, AR, Safar, F, Gage, FH. (1999) Fibroblast growth factor-2 activates a latent neurogenic program in neural stem cells from diverse regions of the adult CNS. *J Neurosci* **19**: 8487-8497.
- Peterson, DA. (2002) Stem cells in brain plasticity and repair. *Curr Opin Pharmacol* **2**: 34-42.

- Pluchino, S, Quattrini, A, Brambilla, E, Gritti, A, Salani, G, Dina, G, Galli, R, Del Carro, U, Amadio, S, Bergami, A, Furlan, R, Comi, G, Vecovi, AL, Martino, G. (2003) Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. *Nature* **422**: 688-694.
- Potten, CS, Loeffler, M. (1990) Stem cells: attributes, cycles, spirals, pitfalls and uncertain lessons for and from the crypt. *Development* **110**: 1001-1120.
- Ramalho-Santos, M, Yoon, S, Matuzaki, Y, Mulligan, R, Melton, DA. (2002) "Stemness": transcriptional profiling of embryonic and adult stem cells. *Science* **298**: 597-600.
- Rossi, F, Cattaneo, E. (2002) Neural stem cell therapy for neurological disease: dreams and reality. *Nature* **3**: 401-409.
- Rowland, LP, Scheider, LA. (2001) Amyotrophic lateral sclerosis. *N Engl J Med* **344**: 1688-1700.
- Sakakibara, S, Okano, H. (1997) Expression of neural RNA-binding proteins in the post-natal CNS: implications of their roles in neuronal and glial cell development. *J Neurosci* **17**: 8300-8312.
- Saporta, S, Kim, JJ, Willing, AE, Fu, ES, Davis, CD, Sanberg, PR. (2003) Human umbilical cord blood stem cells infusion in spinal cord injury: engraftment and beneficial influence on behavior. *J Hematother Stem Cell Res* **12**: 271-278.
- Schmidt, W, Reymann, KG. (2002) Proliferating cells differentiate into neurons in the hippocampal CA1 region of gerbils after global cerebral ischemia. *Neurosci Lett* **334**: 153-156.
- Seaberg, RM, van der Kooy, D. (2003) Stem and progenitor cells: the premature desertion of rigorous definition. *Trends Neurosci* **26**: 125-131.
- Shimazaki, T, Shingo, T, Weiss, S. (2001) The ciliary neurotrophic factor/leukemia inhibitory factor/gp130 receptor complex operates in the maintenance of mammalian forebrain neural stem cells. *J Neurochem* **21**: 7642-7653.
- Silani, V, Fogh, I, Ratti, A, Sassone, J, Ciammola, A, Cova, L. (2002) Stem cells in the treatment of amyotrophic lateral sclerosis (ALS). *Amyotroph Lateral Scler Other Motor Neuron Disord* **3**: 173-181.
- Silani, V, Leigh, N. (2003) Stem cell therapy for ALS: hope and reality. *Amyotroph Lateral Scler Other Motor Neuron Disord* **4**: 1-3.
- Slutsky, SG, Kamaraju, AK, Levy, AM, Chebath, J, Revel, M. (2003) Activation of myelin genes during transdifferentiation from melanoma to glial cell phenotype. *J Biol Chem* **278**: 8960-8968.
- Steindler, DA, Pincus, DW. (2002) Stem cells and neurogenesis in the adult human brain. *Lancet* **359**: 1047-1054.
- Tada, T, Tada, M. (2001) Toti-/pluripotential stem cells and epigenetic modifications. *Cell Struct Funct* **26**: 149-160.
- Taupin, P, Gage, FH. (2002) Adult neurogenesis and neural stem cells of the central nervous system in mammals. *J Neurosci Res* **69**: 745-749.
- Temple, S. (2001) The development of neural stem cells. *Nature* **414**: 112-117.
- Terada, N, Hamazaki, T, Oka, M, Hoki, M, Mastlalerz, DM, Nakano, Y, Meyer, EM, Morel, L, Peterson, B, Scott, EW. (2002) Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. *Nature* **416**: 542-545.
- Toma, JG, Akhavan, M, Fernandes, KJL, Barnabè-Heider, D, Sadikot, A, Kaplan, DR, Miller, FD. (2001) Isolation of multipotent adult stem cells from the dermis of mammalian skin. *Nat Cell Biol* **3**: 778-784.
- van Heyningen, P, Calver, AR, Richardson, WD. (2001) Control of progenitor cell number by mitogen supply and demand. *Curr Biol* **11**: 232-241.
- Vassilopoulos, G, Wang, PR, Russel, DW. (2003) Transplanted bone marrow regenerates liver by cells fusion. *Nature* **422**: 901-904.
- Vastag, B. (2001) Stem cell step closer to the clinic: paralysis partially reversed in rats with ALS-like disease. *JAMA* **285**: 1691-1693.
- Verfaillie, CM, Pera, MF, Lansdorp, PM. (2002) Stem cells: hype and reality. *Hematology (Am Soc Hematol Educ Program)* **2002**: 369-391.
- Wagers, AJ, Sherwood, RI, Christensen, JL, Weissman, IL. (2002) Little evidence for developmental plasticity of adult hematopoietic stem cells. *Science* **297**: 2256-2259.
- Wang, X, Willenbring, H, Akkari, Y, Torimaru, Y, Foster, M, Al-Dhalimy, M, Lagasse, E, Finegol, M, Olson, S, Grompe, M. (2003) Cell fusion is the principal source of bone-marrow-derived hepatocytes. *Nature* **422**: 897-901.
- Weissman, IL, Anderson, DJ, Gage, F. (2001) Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. *Ann Rev Cell Dev Biol* **17**: 387-403.
- Weissman, IL, Anderson, DJ, Gage, F. (2001) Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiation. *Annu Rev Cell Dev Biol* **17**: 387-403.
- Wernig, M, Brustle, O. (2002) Fifty ways to make a neuron: shifts in stem cell hierarchy and their implications for neuropathology and repair. *J Neuropathol Exp Neurol* **61**: 101-110.
- Wong, PC, Cai, H, Borchelt, DR, Price, DL. (2002) Genetically engineered mouse models of neurodegenerative diseases. *Neuroscience* **5**: 633-639.
- Wring, LS, Li, J, Caldwell, MA, Wallace, K, Johnson, JA, Svendsen, CN. (2003) Gene expression in human neural stem cells: effects of leukemia inhibitory factor. *J Neurochem* **86**: 179-195.
- Wroblewski, J, Engstrom, M, Edwall-Arvidsson, C, Sjoberg, G, Sejersen, T, Lendahl, U. (1997) Distribution of nestin in the developing mouse limb bud *in vivo* and in micro-mass cultures of cells isolated from limb buds. *Differentiation* **61**: 151-159.
- Wu, S, Suzuki, Y, Kitada, M, Kataoka, K, Kitaura, M, Chou, H, Nishimura, C, Ide, C. (2002) New method for transplantation of neurosphere cells into injured spinal cord through cerebrospinal fluid in rat. *Neurosci Lett* **318**: 81-84.
- Wurmser, AE, Gage, FH. (2002) Cell fusion causes confusion. *Nature* **416**: 485-487.
- Yamamoto, S, Yamamoto, N, Kitamura, T, Nakafuku, M. (2001) Proliferation of parenchymal neural progenitors in response to injury in the adult rat spinal cord. *Exp Neurol* **172**: 1115-1127.
- Ying, QL, Nicholson, J, Evans, EP, Smith, AG. (2002) Changing potency by spontaneous fusion. *Nature* **416**: 545-548.
- Zhao, LR, Dian, WM, Reyes, M, Keene, CD, Verfaillie, CM, Low, WC. (2002) Human bone marrow stem cells exhibit neuronal phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. *Exp Neurol* **174**: 11-20.
- Zuccato, C, Ciammola, A, Rigamonti, D, Leavitt, BR, Goffredo, D, Conti, L, MacDonald, ME, Friedlander, RM, Silani, V, Hayden, MR, Timmusk, T, Sipione, S, Cattaneo, E. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. *Science* **293**: 493-498.

Copyright of Current Neurovascular Research is the property of Bentham Science Publishers Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.